Tachycardia in Adults

Overview

Tachycardia, defined as a heart rate exceeding 100 beats per minute in adults, represents a heterogeneous group of cardiac rhythm disturbances with widely varying clinical significance. The spectrum ranges from physiological sinus tachycardia—an appropriate compensatory response to metabolic demand—to life-threatening ventricular arrhythmias requiring immediate intervention. Accurate differentiation between benign and pathological tachycardias is a cornerstone of emergency cardiovascular care.

The clinical challenge lies in rapid and accurate diagnosis, particularly distinguishing supraventricular from ventricular origins, and identifying unstable patients requiring immediate electrical cardioversion. Wide complex tachycardia (QRS ≥120 ms) poses particular diagnostic difficulty, with 75-80% representing ventricular tachycardia (VT) despite the tendency to diagnose supraventricular tachycardia (SVT) with aberrancy. [1] This diagnostic bias can have fatal consequences, as misdiagnosis of VT as SVT and inappropriate treatment with AV nodal blocking agents can precipitate hemodynamic collapse.

The management of tachyarrhythmias has evolved significantly with advances in pharmacological therapies, electrical cardioversion protocols, and definitive catheter ablation techniques. The 2019 ESC Guidelines for supraventricular tachycardia and 2017 AHA/ACC/HRS Guidelines for ventricular arrhythmias provide evidence-based frameworks for diagnosis and treatment. [2,3] This topic provides comprehensive, exam-focused coverage of tachycardia diagnosis and management essential for MRCP, ACLS certification, and emergency medicine practice.

---

Epidemiology

Incidence and Prevalence

Supraventricular Tachycardias

• Paroxysmal SVT: Prevalence 2.25 per 1,000 persons, incidence 35 per 100,000 person-years [4]
• Female predominance (2:1 ratio for AVNRT)
• Atrial fibrillation: Most common sustained arrhythmia, affecting 2-4% of adults > 65 years [5]
• Atrial flutter: Prevalence 0.4-1% in general population

Ventricular Tachycardias

• Monomorphic VT: Predominantly in patients with structural heart disease
• Post-MI patients: 3-5% develop sustained VT within first year
• Polymorphic VT (Torsades de Pointes): Rare, associated with QT prolongation (acquired or congenital)

Accessory Pathway Syndromes

• Wolff-Parkinson-White (WPW) syndrome: 0.1-0.3% of general population [6]
• Manifest pre-excitation more common in males (60-70%)
• Risk of sudden cardiac death in WPW: 0.15-0.39% over lifetime

Risk Factors

---

Aetiology & Pathophysiology

Electrophysiological Mechanisms

1. Enhanced Automaticity Normal cardiac pacemaker cells exhibit spontaneous phase 4 depolarization. Enhanced automaticity occurs when:

• Sinus node rate increases (physiological response to catecholamines, fever, hypovolemia)
• Ectopic foci develop abnormal automaticity (ectopic atrial tachycardia, accelerated idioventricular rhythm)

2. Triggered Activity

• Early Afterdepolarizations (EADs): Occur during repolarization (phases 2-3), typically in setting of prolonged QT interval. Mechanism of Torsades de Pointes polymorphic VT
• Delayed Afterdepolarizations (DADs): Occur after complete repolarization (phase 4), triggered by intracellular calcium overload. Classic mechanism in digitalis toxicity

3. Re-entry (Most Common Mechanism for SVT and VT) Re-entry requires anatomical or functional circuit with:

1. Two distinct conduction pathways with different refractory periods
2. Unidirectional block in one pathway
3. Slow conduction through alternate pathway allowing recovery
4. Re-excitation of initially blocked pathway creating self-sustaining circuit

Exam Detail: ### Molecular Basis of Re-entry

Critical Parameters:

• Wavelength = Conduction velocity × Refractory period
• Re-entry possible when circuit length > wavelength
• Antiarrhythmic drugs work by either:
  • ↑ Refractory period (Class III: amiodarone, sotalol)
  • ↓ Conduction velocity (Class I: procainamide, flecainide)
  • Both effects (Class III drugs also affect conduction)

Specific Re-entrant Circuits:

1. AVNRT (AV Nodal Re-entrant Tachycardia)

   • Dual AV nodal pathways: Fast pathway (short RP) and slow pathway (long RP)
   • Typical (Slow-Fast) AVNRT (90%): Antegrade via slow pathway, retrograde via fast
   • Atypical (Fast-Slow) AVNRT (10%): Reverse circuit, long RP tachycardia
   • P waves often buried in QRS or appear as pseudo-r' in V1, pseudo-S in inferior leads

2. AVRT (AV Re-entrant Tachycardia)

   • Requires accessory pathway (Bundle of Kent) bypassing AV node
   • Orthodromic AVRT (90-95%): Antegrade via AV node, retrograde via accessory pathway → Narrow complex
   • Antidromic AVRT (5-10%): Antegrade via accessory pathway, retrograde via AV node → Wide complex
   • P wave visible after QRS (RP interval less than PR interval)

3. Atrial Flutter

   • Typical (Type I): Macro-reentrant circuit around tricuspid annulus (cavotricuspid isthmus dependent)
   • Counter-clockwise rotation (most common): Negative sawtooth in II, III, aVF
   • Atrial rate typically 250-350 bpm, commonly conducts 2:1 → ventricular rate ~150 bpm
   • Atypical (Type II): Left atrial or non-isthmus dependent circuits

4. Ventricular Tachycardia

   • Scar-related VT: Re-entry around myocardial infarction scar tissue
   • Circuit involves slow conduction zones in border zone of infarct
   • Monomorphic appearance reflects stable re-entrant circuit
   • Bundle branch re-entry: Less common, seen in dilated cardiomyopathy

Wolff-Parkinson-White (WPW) Syndrome - Detailed Pathophysiology

Accessory Pathway Characteristics

• Muscular connection between atria and ventricles bypassing AV node
• No decremental conduction properties (unlike AV node)
• Can conduct at extremely rapid rates (up to 300-400 bpm)

ECG Features During Sinus Rhythm

• Short PR interval (less than 120 ms) - rapid conduction bypasses AV node delay
• Delta wave - slurred upstroke of QRS from ventricular pre-excitation
• Widened QRS complex - fusion of pre-excited and normal conduction
• ST-T wave abnormalities (discordant to QRS vector)

Life-Threatening Risk: Pre-excited Atrial Fibrillation When AF develops in patient with WPW:

1. Atrial impulses conducted directly to ventricles via accessory pathway
2. No AV nodal filtering → extremely rapid ventricular rates (often > 250 bpm)
3. Very short R-R intervals (less than 250 ms) increase VF risk
4. Sudden cardiac death mechanism in WPW (incidence 0.15-0.39% over lifetime) [6]

Critical Management Principle AV nodal blocking agents (adenosine, beta-blockers, calcium channel blockers, digoxin) are contraindicated in pre-excited AF:

• Block AV node, forcing all conduction via accessory pathway
• Paradoxical increase in ventricular rate
• Can precipitate ventricular fibrillation [7]
• ONLY procainamide or ibutilide (block accessory pathway) or electrical cardioversion

---

Clinical Presentation

Symptoms

Cardinal Symptoms

• Palpitations (80-90%): Sudden onset and offset characteristic of paroxysmal SVT
• Dyspnea (40-60%): Due to reduced diastolic filling time and cardiac output
• Chest discomfort (30-50%): May indicate rate-related ischemia ("demand ischemia")
• Dizziness/lightheadedness (30-40%): Cerebral hypoperfusion
• Syncope or near-syncope (10-20%): Indicates significant hemodynamic compromise

Specific Symptom Patterns

Polyuria in SVT: Pathognomonic symptom resulting from atrial stretch → atrial natriuretic peptide (ANP) release → diuresis. Occurs within minutes of termination.

Physical Examination

Vital Signs

• Heart rate: Typically 140-280 bpm for SVT, 100-250 bpm for VT
• Blood pressure: May be normal, elevated (catecholamine surge), or reduced (hemodynamic compromise)
• Respiratory rate: Often elevated if heart failure developing

Cardiac Examination Findings

Signs of Hemodynamic Instability (Require Immediate Cardioversion)

• Systolic BP less than 90 mmHg with symptoms
• Altered mental status (confusion, decreased responsiveness)
• Signs of shock (cool, clammy skin; delayed capillary refill; weak pulses)
• Ischemic chest pain with ECG changes
• Acute pulmonary edema (severe dyspnea, hypoxemia, bilateral crackles)

---

ECG Diagnosis and Differentiation

Systematic Approach to Tachycardia ECG

Step 1: Measure Heart Rate

• Tachycardia defined as HR > 100 bpm
• Severe tachycardia > 150 bpm often pathological

Step 2: Assess QRS Width

• Narrow complex: QRS less than 120 ms → Origin at or above bundle of His → SVT
• Wide complex: QRS ≥120 ms → Ventricular origin OR SVT with aberrant conduction

Step 3: Determine Regularity

• Regular: Measure R-R interval variation
• Irregular: Categorize pattern (irregularly irregular vs regularly irregular)

Step 4: Identify P Waves and AV Relationship

• P wave morphology and axis
• P wave relationship to QRS (1:1, 2:1, variable, dissociated)

Narrow Complex Tachycardia (QRS less than 120 ms) - Detailed Differential

Regular Narrow Complex Tachycardia

1. Sinus Tachycardia

   • Rate: 100-150 bpm (rarely > 140 in resting adults)
   • P waves: Normal (upright I, II, aVF; inverted aVR)
   • Gradual onset and offset
   • Identify and treat underlying cause

2. AVNRT (AV Nodal Re-entrant Tachycardia)

   • Rate: 150-250 bpm (typically 160-220 bpm)
   • P waves: Usually not visible (buried in QRS)
   • Pseudo r' wave in V1 (retrograde P wave terminal portion of QRS)
   • Pseudo S wave in inferior leads (II, III, aVF)
   • Abrupt onset/offset
   • Most common regular SVT in adults without structural disease

3. AVRT (AV Re-entrant Tachycardia) - Orthodromic

   • Rate: 150-250 bpm
   • P waves: Visible after QRS in ST segment or early T wave
   • RP interval less than PR interval (short RP tachycardia)
   • Retrograde P often negative in II, III, aVF
   • History of WPW or previous ablation

4. Atrial Flutter with Fixed AV Block

   • Atrial rate: 250-350 bpm (typically 300 bpm)
   • 2:1 AV conduction: Ventricular rate ~150 bpm (very common)
   • Sawtooth flutter waves: Best seen in II, III, aVF (negative deflections)
   • Also visible in V1 (positive deflections)
   • May require increased AV block to visualize: vagal maneuvers or adenosine transiently block AV node → reveal flutter waves

5. Ectopic Atrial Tachycardia

   • Rate: 100-250 bpm
   • Abnormal P wave morphology (different from sinus)
   • Isoelectric baseline between P waves (distinguishes from flutter)
   • Often "warm-up" and "cool-down" phenomenon
   • Associated with structural disease, digoxin toxicity, COPD

Irregular Narrow Complex Tachycardia

1. Atrial Fibrillation

   • Irregularly irregular R-R intervals
   • No discernible P waves
   • Fibrillatory baseline (fine or coarse)
   • Ventricular rate typically 110-180 bpm if untreated
   • Most common pathological arrhythmia

2. Atrial Flutter with Variable AV Block

   • Irregular R-R intervals but flutter waves visible
   • Variable conduction (2:1, 3:1, 4:1 changing)
   • Sawtooth pattern maintains constant rate

3. Multifocal Atrial Tachycardia (MAT)

   • ≥3 different P wave morphologies
   • Varying PR and R-R intervals
   • Rate typically 100-150 bpm
   • Associated with severe pulmonary disease (COPD, hypoxia)
   • Treatment focuses on underlying lung disease

Wide Complex Tachycardia (QRS ≥120 ms) - Critical Differentiation

GOLDEN RULE: Assume VT until proven otherwise

• 75-80% of wide complex tachycardias are VT [1]
• Misdiagnosis of VT as SVT with aberrancy is potentially fatal
• Treating VT with AV nodal blockers (verapamil) can cause cardiovascular collapse

Differential Diagnosis

1. Ventricular Tachycardia (75-80%)
2. SVT with pre-existing bundle branch block (15-20%)
3. SVT with rate-related aberrant conduction (5%)
4. Antidromic AVRT (pre-excited tachycardia via accessory pathway) (less than 5%)
5. Pacemaker-mediated tachycardia
6. Hyperkalemia with widened QRS

Brugada Criteria for VT vs SVT (Stepwise Algorithm)

High sensitivity (98.7%) and specificity (96.5%) for VT diagnosis [8]

Step 1: Absence of RS complex in ALL precordial leads?

• If YES → VT (no RS in V1-V6 indicates abnormal ventricular activation)
• If NO → proceed to Step 2

Step 2: R to S interval > 100 ms in ANY precordial lead?

• Measure from beginning of R wave to nadir of S wave
• If YES → VT (slow ventricular conduction)
• If NO → proceed to Step 3

Step 3: AV dissociation present?

• Look for independent P waves (dissociated from QRS)
• Capture beats: Occasional normal QRS when sinus impulse captures ventricles
• Fusion beats: Hybrid QRS morphology (simultaneous sinus and ventricular activation)
• If YES → VT (pathognomonic finding)
• If NO → proceed to Step 4

Step 4: Morphology criteria for VT in V1-V2 AND V6

If RBBB pattern (dominant R in V1):

• V1: Monophasic R or QR or RS with R/S > 1 → VT
• V6: R/S ratio less than 1 (dominant S wave) → VT

If LBBB pattern (dominant S in V1):

• V1: R wave > 30 ms, notched S downstroke, > 60 ms to nadir of S → VT
• V6: Q or QS wave → VT

If none of above criteria met → SVT with aberrancy

Exam Detail: ### Additional Criteria Favoring VT

Clinical Factors

• Age > 35 years (VT increases with age)
• History of myocardial infarction (scar-related VT)
• History of heart failure or cardiomyopathy
• Hemodynamic stability does NOT exclude VT (many VT patients remain conscious)

ECG Findings Strongly Favoring VT

• Northwest axis (-90° to -180°): Extreme axis deviation, very unusual for SVT
• Positive or negative QRS concordance in V1-V6:
  • All positive (concordant positive) → VT
  • All negative (concordant negative) → VT
  • Normal SVT shows R/S transition in V3-V4
• Very wide QRS (> 140 ms with RBBB morphology, > 160 ms with LBBB)
• Specific VT patterns:
  • "Right ventricular outflow tract (RVOT) VT: LBBB pattern with inferior axis"
  • "Fascicular VT: RBBB pattern with left axis"

Josephson Sign: Small notch near nadir of S wave in V1 or V2 → VT

Specific Arrhythmia Patterns

Polymorphic Ventricular Tachycardia

1. Torsades de Pointes ("Twisting of the Points")

   • Continuously changing QRS morphology and axis
   • QRS appears to twist around baseline
   • Associated with prolonged QT interval (QTc > 500 ms typically)
   • Rate 200-250 bpm, often self-terminates but can degenerate to VF

   Causes of Acquired QT Prolongation:

   • Medications: Class IA/III antiarrhythmics, antipsychotics, antibiotics (fluoroquinolones, macrolides), antifungals
   • Electrolytes: Hypokalemia, hypomagnesemia, hypocalcemia
   • Bradycardia
   • Congenital long QT syndrome (LQTS)

2. Polymorphic VT with Normal QT

   • Acute ischemia/MI
   • Consider urgent coronary angiography

Bidirectional Ventricular Tachycardia

• Alternating QRS axis beat-to-beat
• Pathognomonic for digitalis toxicity
• Also: catecholaminergic polymorphic VT (CPVT)

---

Red Flags and Immediate Threats

Hemodynamic Instability - Immediate Cardioversion Indications

The 2015 AHA ACLS Guidelines define unstable tachycardia as presence of ANY: [9]

Key Principle: Do NOT delay cardioversion to obtain IV access or sedate if patient is critically unstable (pulseless or near-pulseless)

High-Risk Tachyarrhythmias

Immediate Life-Threats Requiring Emergent Intervention

1. Polymorphic VT / Torsades de Pointes

   • Risk of degeneration to VF
   • Do NOT use synchronized cardioversion (polymorphic rhythm confuses sync mechanism)
   • Use unsynchronized defibrillation if unstable
   • Magnesium sulfate 2 g IV first-line pharmacological
   • Correct QT-prolonging factors

2. Pre-excited Atrial Fibrillation (WPW + AF)

   • Very rapid rate (> 250 bpm) with irregular wide complexes
   • Varying QRS width (degree of pre-excitation varies)
   • Risk of VF
   • Avoid AV nodal blockers (adenosine, beta-blockers, CCBs, digoxin)
   • Use procainamide or immediate cardioversion

3. Ventricular Tachycardia with Pulse

   • Risk of hemodynamic deterioration and sudden death
   • Even if stable, requires urgent treatment
   • Amiodarone or procainamide if stable
   • Synchronized cardioversion if unstable

4. Extremely Rapid Tachycardia (> 220 bpm)

   • Very short diastolic filling time → reduced cardiac output
   • May indicate accessory pathway conduction (WPW)
   • High risk if underlying structural disease

---

Investigations

Essential Investigations

12-Lead ECG (IMMEDIATE - within 10 minutes)

• Must be obtained before any treatment (except in pulseless arrest)
• Classify tachycardia (narrow vs wide, regular vs irregular)
• Identify specific arrhythmia patterns
• Assess for ischemia, strain, QT prolongation
• Compare to prior ECGs if available (check for baseline BBB, WPW)

Continuous Cardiac Monitoring

• Mandatory for all tachyarrhythmias
• Monitor response to interventions
• Detect recurrence or deterioration

Laboratory Investigations

Point-of-Care Testing

• Venous blood gas: Rapid electrolytes, lactate (if shock)
• Glucose: Hypoglycemia can cause tachycardia

Imaging and Specialized Tests

Chest Radiograph

• Cardiomegaly (chronic heart disease)
• Pulmonary edema (acute heart failure)
• Pneumonia, COPD (MAT, sinus tachycardia)

Echocardiography (Not Acute, but Important)

• Structural heart disease assessment
• Left ventricular function (EF)
• Valvular disease
• Wall motion abnormalities (prior MI)
• Consider in all patients with new arrhythmia

CT Pulmonary Angiography

• If pulmonary embolism suspected (tachycardia, dyspnea, hypoxia, risk factors)

---

Management

Immediate Assessment and Stabilization (ABCDE)

A - Airway

• Ensure patent airway
• Prepare for airway management if cardioversion required with sedation

B - Breathing

• Administer oxygen if hypoxic (SpO2 less than 94%)
• Assess for pulmonary edema

C - Circulation

• Obtain IV access (large-bore peripheral or central if unstable)
• Continuous cardiac monitoring
• 12-lead ECG

D - Disability

• Assess mental status (GCS)
• Altered consciousness indicates instability

E - Exposure

• Look for signs of underlying cause (thyroid, infection)

Management Algorithm Overview

TACHYCARDIA (HR > 100 bpm)
         ↓
    12-LEAD ECG
         ↓
HEMODYNAMICALLY UNSTABLE?
(Hypotension, AMS, ischemia, pulmonary edema)
         ↓
    YES  |  NO
         |      ↓
    CARDIOVERT   QRS WIDTH?
         |        ↓
         |   NARROW (less than 120ms) | WIDE (≥120ms)
         |        ↓                 ↓
         |   REGULAR?          ASSUME VT
         |        ↓                 ↓
         |   YES  |  NO       Amiodarone or
         |    ↓       ↓       Cardioversion
         | Vagal  AF/Flutter
         | Adenosine  Rate control

---

Treatment of Unstable Tachycardia

Synchronized Cardioversion Protocol

Indications for Immediate Cardioversion

• Systolic BP less than 90 mmHg with symptoms
• Acutely altered mental status
• Signs of shock
• Ischemic chest discomfort with ST changes
• Acute heart failure/pulmonary edema

Pre-Cardioversion Checklist

1. ✅ Confirm rhythm on monitor
2. ✅ Ensure adequate oxygenation
3. ✅ IV access established
4. ✅ Activate SYNC mode (except for polymorphic VT / pulseless VT)
5. ✅ Sedate if conscious (midazolam 1-2 mg IV or etomidate 0.2 mg/kg)
6. ✅ Consider brief pre-oxygenation

Energy Levels for Synchronized Cardioversion [9]

Post-Cardioversion Management

• Monitor for 4-6 hours minimum
• Reassess ECG for underlying abnormalities (WPW, prolonged QT)
• Consider antiarrhythmic therapy to prevent recurrence
• Cardiology consultation
• Address underlying causes

Clinical Pearl: Cardioversion Pearls:

• SYNC mode is essential for organized rhythms to avoid R-on-T phenomenon (can precipitate VF)
• Pad placement: Anteroposterior positioning may be more effective than anterolateral for AF
• Delayed capture: If cardioversion fails, check pad contact, increase energy, consider different pad position
• Post-cardioversion arrhythmias: Brief bradycardia or ectopy common, usually self-limiting
• Anticoagulation for AF: If AF > 48 hours or unknown duration, heparin infusion or LMWH after cardioversion + warfarin/DOAC for 4 weeks minimum

---

Treatment of Stable Narrow Complex Tachycardia

Vagal Maneuvers

Modified Valsalva Maneuver (Superior to Standard Valsalva) The REVERT trial (2015) demonstrated superiority of modified Valsalva over standard technique (43% vs 17% conversion rate for SVT). [10]

Technique:

1. Patient semi-recumbent (45°)
2. Blow into 10 mL syringe to generate 40 mmHg pressure for 15 seconds
3. Immediately lay patient supine
4. Passive leg raise to 45° for 15 seconds
5. Return to semi-recumbent position
6. Monitor for conversion (often occurs during reperfusion phase)

Other Vagal Maneuvers

• Carotid sinus massage: Contraindicated if carotid bruit or history of TIA/stroke
  • "Technique: Firm pressure at carotid bifurcation (angle of jaw) for 5-10 seconds"
  • Never perform bilaterally simultaneously
• Diving reflex: Ice water to face or immerse face in ice water for 10-15 seconds

Adenosine Protocol

Mechanism: Ultra-short-acting purinergic receptor agonist, causes transient AV nodal block (6-10 seconds)

Indications

• Regular narrow complex tachycardia (likely AVNRT or AVRT)
• Diagnostic tool for wide complex tachycardia of uncertain etiology
• Atrial flutter (reveals flutter waves when AV block induced)

Contraindications

• Second- or third-degree AV block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Known severe asthma (can cause bronchospasm) - relative contraindication
• Pre-excited AF (irregular wide complex) - can precipitate VF
• Recently caffeinated patients (competitive antagonist)

Dosing Protocol [11]

Technique for Optimal Success

• Use large peripheral IV or antecubital vein (or central line)
• Patient supine
• Three-way stopcock setup: Adenosine - patient - flush
• Rapid push (1-2 seconds) immediately followed by rapid flush
• Continuous ECG monitoring and recording
• Warn patient: "You will feel very unpleasant for 10-20 seconds - chest tightness, flushing, sense of doom - this is normal and will pass quickly"

Special Dosing Considerations

• Central line: Reduce initial dose to 3 mg (faster circulation time)
• Heart transplant patients: Very sensitive, use 1-2 mg initially (denervated heart)
• Dipyridamole therapy: Reduce dose (dipyridamole blocks adenosine reuptake)
• Theophylline/caffeine: May require higher doses (competitive antagonists)
• Carbamazepine: Potentiates effects, use lower doses

Expected Responses

Adverse Effects (Brief, Self-Limiting)

• Flushing (common, 30-40%)
• Chest discomfort / sense of impending doom (common, 20-30%)
• Dyspnea (10-20%)
• Transient bradycardia or asystole (expected, usually less than 6 seconds)
• Brief hypotension
• Bronchospasm (rare, especially in asthmatics)

Exam Detail: ### Adenosine Diagnostic Use in Wide Complex Tachycardia

Adenosine can safely differentiate SVT with aberrancy from VT in stable patients:

If SVT with aberrancy:

• Will often terminate (if AVNRT/AVRT)
• Or will demonstrate transient AV block revealing underlying atrial rhythm

If VT:

• Usually no effect (VT independent of AV node)
• Exception: Adenosine-sensitive VT (RVOT-VT, fascicular VT) may terminate
• These are typically structurally normal hearts with specific VT types

Safety: Large case series show adenosine safe in wide complex tachycardia with appropriate monitoring, though amiodarone or cardioversion preferred if VT suspected. [12]

Pharmacological Rate Control for Atrial Fibrillation/Flutter

When Regular Rhythm Breaks to Irregular (AF Suspected)

• Vagal maneuvers and adenosine ineffective for AF
• Goals: Rate control (less than 110 bpm at rest) and assess for rhythm control vs anticoagulation

First-Line Rate Control Agents

1. Diltiazem (Non-dihydropyridine Calcium Channel Blocker)

   • Loading: 0.25 mg/kg IV (15-20 mg typical) over 2 minutes
   • Assess response at 15 minutes
   • Second dose: 0.35 mg/kg (20-25 mg typical) if inadequate rate control
   • Maintenance infusion: 5-15 mg/hour
   • Advantages: Effective, well-tolerated, safe in COPD
   • Cautions: Hypotension (5-10%), avoid in decompensated heart failure (negative inotrope)

2. Metoprolol (Cardioselective Beta-Blocker)

   • Dose: 2.5-5 mg IV over 2 minutes
   • Repeat every 5 minutes up to 3 doses (total 15 mg)
   • Advantages: Also controls sympathetic symptoms
   • Contraindications: Asthma, COPD (relative), decompensated heart failure, hypotension
   • Alternative: Esmolol (ultra-short-acting, 0.5 mg/kg load then infusion)

3. Digoxin (Cardiac Glycoside)

   • Loading: 0.5 mg IV, then 0.25 mg IV every 6 hours x 2 doses (total 1-1.5 mg over 24h)
   • Onset: Slow (2-6 hours)
   • Advantages: Safe in heart failure, increases contractility
   • Disadvantages: Slow onset, less effective in high catecholamine states, narrow therapeutic window
   • Indications: Heart failure with AF, sedentary patients
   • Check renal function (renally excreted)

4. Amiodarone (Class III Antiarrhythmic)

   • Use when other agents contraindicated or ineffective
   • Loading: 150 mg IV over 10 minutes, then 1 mg/min x 6 hours, then 0.5 mg/min x 18 hours
   • Advantages: Effective for rate and rhythm control, safe in heart failure and structural disease
   • Cautions: Hypotension (slow infusion rate), phlebitis (use central line for prolonged infusion)

Rate Control Targets [5]

• Lenient control: Resting HR less than 110 bpm (adequate for most patients)
• Strict control: Resting HR less than 80 bpm, less than 110 bpm with exertion (if symptoms persist)
• RACE II trial: Lenient control non-inferior to strict control for outcomes

Rhythm Control (Pharmacological Cardioversion) for AF

Patient Selection for Rhythm Control

• Symptom-driven strategy
• AF duration less than 48 hours (or therapeutic anticoagulation x3 weeks, or TEE-guided)
• Younger patients, first episode, symptomatic despite rate control
• Absence of significant structural heart disease (for certain agents)

Pharmacological Cardioversion Agents

1. Flecainide (Class IC)

   • Indication: Structurally normal heart only
   • Dose: 200-300 mg PO or 2 mg/kg IV over 10 min (max 150 mg)
   • Efficacy: 60-70% conversion within 6 hours
   • Contraindication: Coronary disease, heart failure, structural disease (proarrhythmic risk)

2. Propafenone (Class IC)

   • Similar profile to flecainide
   • Dose: 450-600 mg PO
   • Structurally normal heart only

3. Ibutilide (Class III)

   • Dose: 1 mg IV over 10 minutes, may repeat once
   • Efficacy: 50-60% for AF, 70-90% for atrial flutter
   • Risk: Torsades de Pointes (3-8%), requires continuous monitoring for 4-6 hours
   • Check QT interval, correct K+ > 4 mEq/L, Mg2+ > 2 mEq/L

4. Amiodarone (Class III)

   • Safe in structural heart disease
   • Loading: 150 mg IV over 10 min, then infusion
   • Efficacy: Modest for acute conversion (20-40% at 24 hours), more effective for preventing recurrence

---

Treatment of Wide Complex Tachycardia

Assume Ventricular Tachycardia - Do NOT Delay Treatment

If Unstable: Immediate synchronized cardioversion 100 J, escalate to 200 J

If Stable: Pharmacological therapy

Amiodarone for Stable Monomorphic VT

First-Line for VT with Pulse [3]

Dosing Regimen:

• Loading dose: 150 mg IV over 10 minutes
• May repeat 150 mg every 10-15 minutes if VT persists
• Maintenance infusion: 1 mg/min for 6 hours (360 mg)
• Then 0.5 mg/min for 18 hours (540 mg)
• Maximum cumulative dose: 2.2 g over 24 hours

Administration:

• Dilute in 5% dextrose (incompatible with saline)
• Use central line if prolonged infusion (phlebitis risk)
• Continuous ECG and BP monitoring

Mechanism: Multiple effects - prolongs action potential duration, blocks sodium, calcium, potassium channels, non-competitive beta-blockade

Adverse Effects:

• Hypotension (most common acute side effect, 15-20%) - slow infusion rate
• Bradycardia
• QT prolongation (usually not proarrhythmic)
• Phlebitis if peripheral IV

Procainamide for Stable Wide Complex Tachycardia

Alternative to Amiodarone, particularly if VT vs SVT uncertain [3]

Dosing:

• Infusion: 20-50 mg/min IV until:
  • Arrhythmia terminates, OR
  • Hypotension develops, OR
  • QRS widens by > 50%, OR
  • Total dose 17 mg/kg administered
• Maintenance: 1-4 mg/min infusion

Advantages:

• Effective for VT and SVT with aberrancy
• Useful for pre-excited AF (blocks accessory pathway)

Disadvantages:

• Hypotension (monitor BP closely)
• Slower administration than amiodarone
• QT prolongation
• Not available in all countries

Lidocaine (Lignocaine) for VT

Previously first-line, now third-line (less effective than amiodarone)

Dosing:

• Loading: 1-1.5 mg/kg IV bolus
• Additional boluses: 0.5-0.75 mg/kg every 5-10 minutes (maximum cumulative 3 mg/kg)
• Maintenance: 1-4 mg/min infusion

Indications:

• Ischemic VT (acute MI)
• Alternative if amiodarone/procainamide unavailable

Cautions:

• CNS effects: Dizziness, confusion, seizures (especially elderly, hepatic impairment)
• Reduce dose in heart failure, liver disease (hepatically metabolized)

Management of Polymorphic VT / Torsades de Pointes

Immediate Priorities:

1. If pulseless/unstable: Unsynchronized defibrillation 120-200 J (cannot sync to polymorphic rhythm)
2. Magnesium sulfate: 2 g IV bolus over 1-2 minutes (even if Mg2+ normal) [13]
   • Follow with 1-2 g/hour infusion
   • Mechanism: Suppresses early afterdepolarizations
3. Correct electrolytes:
   • K+ to 4.5-5.0 mEq/L
   • Mg2+ to > 2 mEq/L
   • Ca2+ to normal range
4. Discontinue QT-prolonging drugs
5. Increase heart rate (shortens QT interval):
   • Isoproterenol 2-10 mcg/min infusion
   • Temporary transvenous pacing to 100-120 bpm (overdrive suppression)

DO NOT USE:

• Class IA or III antiarrhythmics (procainamide, amiodarone, sotalol) - further prolong QT
• Synchronized cardioversion (ineffective for polymorphic rhythm)

Definitive Treatment:

• Identify and remove QT-prolonging agents
• Screen for congenital long QT syndrome (LQTS) if no clear precipitant
• Beta-blockers and ICDs for congenital LQTS

---

Management of Pre-excited Atrial Fibrillation (WPW + AF)

Recognition:

• Irregular wide complex tachycardia
• Very rapid rate (often > 200-250 bpm)
• Varying QRS width (pathognomonic - degree of pre-excitation varies)
• Shortest R-R interval less than 250 ms suggests high-risk pathway

CRITICAL MANAGEMENT ERRORS TO AVOID [7]

❌ DO NOT USE AV nodal blocking agents:

• Adenosine
• Beta-blockers (metoprolol, esmolol)
• Calcium channel blockers (diltiazem, verapamil)
• Digoxin

Mechanism of Harm: These agents block AV node preferentially → increase conduction via accessory pathway → paradoxical acceleration → ventricular fibrillation

CORRECT MANAGEMENT:

1. If Unstable: Immediate Cardioversion

   • 120-200 J biphasic synchronized

2. If Stable: Procainamide (First-Line Pharmacological)

   • 20-50 mg/min IV (as per VT protocol above)
   • Mechanism: Blocks accessory pathway conduction
   • Slows conduction and may convert to sinus rhythm

3. Alternative: Ibutilide

   • 1 mg IV over 10 minutes
   • Monitor for Torsades (QT prolongation)

4. Long-Term: Electrophysiology Study and Catheter Ablation

   • Definitive cure for WPW (success rate > 95%)
   • Eliminates sudden death risk
   • All patients with symptomatic WPW should be referred

Clinical Pearl: Identifying Pre-excited AF:

• History of WPW or "weird ECG" in past
• Very rapid irregular rate (> 220 bpm should raise suspicion)
• Delta waves visible intermittently when rate varies
• Varying QRS width (some beats more pre-excited than others)
• If in doubt: Avoid AV nodal blockers, use procainamide or cardiovert

---

Special Populations

Pregnancy

Physiological Changes:

• Increased HR, stroke volume, cardiac output
• Sinus tachycardia common (HR up to 100-110 bpm normal)
• Increased ectopy and palpitations

Arrhythmia Management:

• SVT occurs in 20-24 per 100,000 pregnancies
• Vagal maneuvers and adenosine are SAFE (first-line)
• Electrical cardioversion SAFE at any gestational age

Safe Medications:

• Adenosine: Category C, safe and effective
• Beta-blockers: Metoprolol, labetalol preferred (Category C)
• Digoxin: Safe (Category C)
• Cardioversion: Safe with fetal monitoring if > 24 weeks

Avoid if Possible:

• Amiodarone: Risk of fetal thyroid dysfunction, developmental delay (Category D)
• Atenolol: Intrauterine growth restriction (use metoprolol instead)
• ACE inhibitors: Teratogenic (not for arrhythmia but may be used in underlying disease)

Heart Failure and Reduced Ejection Fraction

Arrhythmia Precipitates and Worsens Heart Failure:

• Loss of AV synchrony
• Rapid rates reduce filling time
• Tachycardia-induced cardiomyopathy if sustained

Safe Agents:

• Amiodarone: Safe in heart failure, first-line for VT or AF with HF
• Digoxin: Positive inotrope, safe for rate control
• Beta-blockers: Use cautiously (can worsen acute decompensation but beneficial long-term)

Avoid:

• Non-dihydropyridine CCBs (diltiazem, verapamil): Negative inotropes, contraindicated in HF with reduced EF
• Class IC agents (flecainide, propafenone): Proarrhythmic in structural disease (CAST trial increased mortality)

Elderly Patients

Considerations:

• Higher prevalence of AF, structural disease
• More sensitive to medications (start lower doses)
• Higher risk of falls with hypotension
• Polypharmacy and drug interactions
• Reduced renal/hepatic clearance (adjust digoxin, amiodarone)

Management:

• Lower threshold for rate control vs rhythm control (AF)
• Careful BP monitoring with rate control agents
• Fall risk assessment
• Assess anticoagulation vs bleeding risk (HAS-BLED score)

Structural Heart Disease and Prior MI

Scar-Related VT:

• Monomorphic VT common post-MI (substrate: scar border zone)
• Amiodarone first-line
• Long-term ICD consideration if EF less than 35%

Avoid Proarrhythmic Agents:

• Class IC drugs (flecainide, propafenone) contraindicated

---

Disposition and Follow-Up

Admission Criteria

ICU/Coronary Care Unit / High-Dependency Unit:

• Cardioversion performed
• Ongoing hemodynamic instability
• Sustained VT (even if terminated)
• Acute MI with arrhythmia
• Heart failure with arrhythmia
• Recurrent arrhythmia despite treatment
• Torsades de Pointes
• High-risk accessory pathway (WPW with pre-excited AF)

Telemetry / Monitored Bed:

• First episode SVT requiring pharmacological termination
• AF with rapid ventricular response requiring IV rate control
• New arrhythmia requiring investigation
• Significant electrolyte disturbance
• Suspected structural heart disease

Discharge Criteria

Patient may be discharged if:

• Stable sinus rhythm or controlled ventricular rate
• Hemodynamically stable for > 6 hours post-intervention
• No evidence of ongoing ischemia
• Electrolytes corrected
• Clear precipitant identified and addressed (e.g., hyperthyroidism, drug effect)
• Appropriate follow-up arranged

Discharge Medications:

• Rate control agents if AF (beta-blocker or CCB)
• Anticoagulation assessment for AF (CHA2DS2-VASc score)
• Anti-arrhythmic prophylaxis if recurrent SVT (beta-blocker)

Outpatient Follow-Up

Cardiology / Electrophysiology Referral Indicated for:

• All patients with ventricular tachycardia
• Recurrent SVT (consider catheter ablation - curative for AVNRT/AVRT)
• WPW syndrome (ablation recommended)
• Atrial flutter (ablation highly effective)
• New AF requiring long-term anticoagulation and rate/rhythm strategy
• Structural heart disease with arrhythmia
• Syncope with arrhythmia

Urgent OP Cardiology (less than 2 weeks):

• VT survivors
• Symptomatic WPW
• Recurrent symptomatic arrhythmia

Routine OP Cardiology (4-6 weeks):

• First episode SVT successfully treated
• New AF requiring anticoagulation decision
• Investigation of structural disease (echocardiography)

---

Prevention and Long-Term Management

Lifestyle Modifications

• Avoid triggers: Caffeine, alcohol, stimulants (individual variability)
• Manage underlying conditions: Hypertension, OSA, obesity
• Smoking cessation
• Adequate sleep and stress management

Pharmacological Prophylaxis

For Recurrent SVT:

• Beta-blockers (metoprolol, bisoprolol) reduce episodes
• Calcium channel blockers (diltiazem, verapamil) for AVNRT
• Consider catheter ablation if frequent/symptomatic (curative)

For AF:

• Rhythm control: Flecainide, propafenone (structurally normal), amiodarone, sotalol, dronedarone
• Rate control: Beta-blockers, CCBs, digoxin
• Anticoagulation: Based on CHA2DS2-VASc score (≥2 men, ≥3 women → anticoagulate)

For VT:

• Beta-blockers (reduce sudden death in post-MI, cardiomyopathy)
• Amiodarone (effective but long-term toxicity)
• ICD placement if high-risk (EF less than 35%, prior sustained VT)

Catheter Ablation - Curative Therapy

High Success Rates for:

• AVNRT: 95-98% success, less than 1% risk AV block requiring pacemaker [2]
• AVRT (WPW): 90-95% success, less than 1% serious complications
• Atrial flutter: 95% success for typical flutter
• Focal atrial tachycardia: 80-90% success
• VT: Variable (60-80% for scar-related VT, > 90% for RVOT-VT)

Indications:

• Symptomatic recurrent SVT despite medical therapy
• Patient preference to avoid long-term medications
• WPW with symptoms (eliminates sudden death risk)
• Atrial flutter (preferred over long-term rate control)

---

Complications

Acute Complications of Tachyarrhythmias

Cardioversion Complications

• Thromboembolism: 1-2% if AF > 48 hours without anticoagulation
• Post-cardioversion arrhythmias: Bradycardia, ectopy (usually transient)
• Skin burns: Rare with modern biphasic waveforms
• Aspiration: If inadequate sedation/airway protection

Long-Term Complications

Tachycardia-Induced Cardiomyopathy

• Chronic rapid heart rate (> 100-120 bpm) for weeks-months → LV dysfunction
• Reversible with rate control or rhythm restoration
• EF improves over 3-6 months after rate control

Atrial Fibrillation Complications

• Stroke (2-7% per year depending on CHA2DS2-VASc)
• Heart failure
• Dementia (increased risk, likely microembolic)
• Reduced quality of life

---

Prognosis

SVT (AVNRT / AVRT)

• Benign in structurally normal hearts
• Recurrence common (50-70% over years) if not ablated
• Excellent prognosis with ablation (95%+ cure rate)
• No increased mortality

Atrial Fibrillation

• Stroke risk: 2-7% per year without anticoagulation (CHA2DS2-VASc dependent)
• Anticoagulation reduces stroke risk by 60-70%
• Increased mortality (1.5-2x) due to comorbidities and complications
• Quality of life impairment

Atrial Flutter

• Similar stroke risk to AF (requires anticoagulation)
• High ablation success rate
• Often progresses to AF over time

Ventricular Tachycardia

• Prognosis depends on underlying heart disease
• Post-MI VT: High recurrence risk, sudden death risk
• Structural heart disease + VT: 5-year mortality 30-50% without ICD
• ICD reduces sudden death by 30-50% in high-risk patients [3]
• VT in structurally normal heart (RVOT-VT, fascicular VT): Excellent prognosis

---

Common Exam Questions and Viva Preparation

Opening Statement for Tachycardia Viva

"Tachycardia is defined as a heart rate greater than 100 beats per minute in adults. My approach to any tachycardia is to first assess hemodynamic stability, then classify the arrhythmia based on QRS width and regularity using a 12-lead ECG. Unstable patients require immediate synchronized cardioversion. For stable patients, I differentiate narrow complex tachycardias—which are supraventricular in origin—from wide complex tachycardias, which I treat as ventricular tachycardia until proven otherwise, given that 75-80% are VT."

High-Yield Exam Topics

1. "How would you differentiate VT from SVT with aberrancy?"

Model Answer: "I would apply the Brugada criteria systematically. First, I look for absence of RS complex in all precordial leads—if present, this indicates VT. Second, I measure the R to S interval; if greater than 100 milliseconds in any precordial lead, this suggests VT. Third, I look for AV dissociation, capture beats, or fusion beats, which are pathognomonic for VT. Fourth, I apply morphology criteria in V1 and V6. Additionally, clinical factors such as age over 35, history of MI, or structural heart disease strongly favor VT. Hemodynamic stability does not exclude VT—many patients with VT remain conscious."

2. "Describe your adenosine administration technique."

Model Answer: "Adenosine is a very short-acting drug with a half-life of approximately 10 seconds, so rapid administration is critical. I would use a large-bore peripheral IV, ideally antecubital, with a three-way stopcock setup. The initial dose is 6 mg given as a rapid 1-2 second push, immediately followed by a 20 mL rapid saline flush. I would have the patient supine with continuous ECG monitoring and recording. I would warn the patient they will experience brief but unpleasant symptoms including chest tightness, flushing, and dyspnea lasting 10-20 seconds. If no conversion after 1-2 minutes, I would give 12 mg, and repeat once more if needed. I would reduce the initial dose to 3 mg if using a central line or if the patient is on dipyridamole, and may need higher doses if the patient has recently consumed caffeine."

3. "A patient presents with irregular wide complex tachycardia at 240 bpm. What is your concern and management?"

Model Answer: "My primary concern is pre-excited atrial fibrillation in a patient with Wolff-Parkinson-White syndrome. The very rapid rate and irregular rhythm with wide complexes, particularly if there is varying QRS width, suggests atrial fibrillation conducting via an accessory pathway. This is a medical emergency as it can degenerate to ventricular fibrillation. It is critical to avoid AV nodal blocking agents including adenosine, beta-blockers, calcium channel blockers, and digoxin, as these will paradoxically accelerate conduction through the accessory pathway. If the patient is hemodynamically unstable, I would perform immediate synchronized cardioversion at 120-200 joules. If stable, I would administer IV procainamide at 20-50 mg per minute, which blocks the accessory pathway. Long-term, this patient requires electrophysiology study and catheter ablation."

4. "What is your approach to polymorphic VT / Torsades de Pointes?"

Model Answer: "Torsades de Pointes is a polymorphic ventricular tachycardia characterized by continuously changing QRS morphology that appears to twist around the baseline, typically associated with QT prolongation. If the patient is pulseless or unstable, I would perform immediate unsynchronized defibrillation at 120-200 joules—synchronized cardioversion cannot work on a polymorphic rhythm. The first-line pharmacological treatment is IV magnesium sulfate 2 grams over 1-2 minutes, even if serum magnesium is normal, followed by an infusion. I would correct electrolytes, targeting potassium 4.5-5.0 and magnesium above 2. I would discontinue all QT-prolonging medications. To suppress further episodes, I would increase the heart rate using isoproterenol infusion or temporary overdrive pacing at 100-120 bpm, as this shortens the QT interval. I would NOT use class IA or III antiarrhythmics as these prolong QT further."

Common Mistakes That Fail Candidates

❌ Assuming hemodynamic stability excludes VT - Many VT patients tolerate the arrhythmia ❌ Using verapamil for wide complex tachycardia - Can cause cardiovascular collapse if VT ❌ Giving AV nodal blockers in WPW with AF - Can precipitate VF ❌ Slow adenosine push - Must be very rapid to reach heart before degradation ❌ Using amiodarone for Torsades - Worsens QT prolongation ❌ Synchronized cardioversion for polymorphic VT - Must be unsynchronized ❌ Forgetting anticoagulation before cardioversion of AF > 48 hours - High stroke risk

---

Key Clinical Pearls

Diagnostic Pearls

1. Regular narrow complex at exactly 150 bpm → Think atrial flutter with 2:1 block (atrial rate 300)
2. Irregularly irregular without P waves → Atrial fibrillation until proven otherwise
3. Polyuria after tachycardia terminates → Pathognomonic for SVT (AVNRT/AVRT)
4. Cannon A waves in neck + wide complex → VT with AV dissociation
5. Very rapid irregular wide complex (> 220 bpm) with varying QRS width → Pre-excited AF (WPW)
6. Rate > 220 bpm in adult → Consider accessory pathway conduction
7. Bidirectional VT (alternating axis) → Digitalis toxicity or CPVT

Treatment Pearls

1. Unstable = Cardiovert immediately - Don't waste time on medications
2. Wide complex = VT until proven otherwise - Treat as VT, you'll save more lives
3. Modified Valsalva 43% success vs standard 17% - Use leg raise technique [10]
4. Adenosine needs RAPID push - 1-2 seconds, immediate flush, or it won't work
5. Polymorphic VT gets magnesium, NOT amiodarone - Amiodarone prolongs QT
6. Pre-excited AF: Procainamide or cardiovert, NEVER AV blockers - Critical safety issue
7. Regular at 150 bpm not responding to adenosine → Give another dose or increase AV block (vagal, adenosine) to reveal flutter waves

Disposition Pearls

1. First VT → Admit even if terminated - Requires investigation, high recurrence risk
2. Recurrent SVT → EP referral - Ablation curative, avoid lifelong medications
3. New AF → Assess CHA2DS2-VASc - Don't discharge without stroke risk assessment
4. WPW → Urgent EP referral - Ablation eliminates sudden death risk
5. Torsades → Admit ICU - High recurrence risk, requires prolonged monitoring and QT-safe environment

---

References

1. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83(5):1649-1659. doi:10.1161/01.CIR.83.5.1649

2. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720. doi:10.1093/eurheartj/ehz467

3. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549

4. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150-157. doi:10.1016/S0735-1097(97)00422-1

5. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665

6. Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern. Heart Rhythm. 2012;9(6):1006-1024. doi:10.1016/j.hrthm.2012.03.050

7. Gaita F, Giustetto C, Riccardi R, et al. Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol. 1989;64(8):487-490. doi:10.1016/0002-9149(89)90424-8

8. Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J. 2007;28(5):589-600. doi:10.1093/eurheartj/ehl473

9. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S444-S464. doi:10.1161/CIR.0000000000000261

10. Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015;386(10005):1747-1753. doi:10.1016/S0140-6736(15)61485-4

11. Lim SH, Anantharaman V, Teo WS, Goh PP, Tan AT. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med. 1998;31(1):30-35. doi:10.1016/S0196-0644(98)70278-X

12. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med. 2006;47(3):217-224. doi:10.1016/j.annemergmed.2005.08.022

13. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77(2):392-397. doi:10.1161/01.CIR.77.2.392

14. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016;133(14):e506-e574. doi:10.1161/CIR.0000000000000311

15. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253

16. Delacretaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. 2006;354(10):1039-1051. doi:10.1056/NEJMcp051145

17. Gupta AK, Thakur RK. Wide QRS complex tachycardias. Med Clin North Am. 2001;85(2):245-266. doi:10.1016/S0025-7125(05)70318-7

18. Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res. 1991;69(6):1427-1449. doi:10.1161/01.RES.69.6.1427

19. Goldberger ZD, Rho RW, Page RL. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia. Am J Cardiol. 2008;101(10):1456-1466. doi:10.1016/j.amjcard.2008.01.024

20. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988

21. Katritsis DG, Camm AJ. Atrioventricular nodal reentrant tachycardia. Circulation. 2010;122(8):831-840. doi:10.1161/CIRCULATIONAHA.110.936591

22. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J. 1967;29(4):469-489. doi:10.1136/hrt.29.4.469

---

Version History

|---------|------|---------|---------------| | 1.0 | 2025-01-15 | Initial comprehensive version | 42/56 | | 2.0 | 2026-01-10 | Gold Standard Enhancement: Expanded to 1,520 lines with 22 PubMed citations. Added comprehensive SVT vs VT differentiation (Brugada criteria), detailed adenosine protocol (REVERT trial), cardioversion indications, WPW pathophysiology and management, antiarrhythmic drug selection algorithms. Enhanced pathophysiology, clinical pearls, exam viva preparation. | 54/56 (Gold) |